St. Paul Global Week brings pilgrims to Tarsus, Türkiye, from 28 to 30 June 2027 for a three-day gathering in the Apostle ...

Transaction structure includes $270 million cash, $180 million equity at $61.38/share, up to $350 million milestones, and low single-digit tiered descending royalties on net sales. Mechanistic ...

Tarsus has agreed to buy Alkeus in an $800 million deal that will give it rights to a drug for rare eye disorder Stargardt disease that has "blockbuster potential." The takeover revolves around Alkeus ...

Tarsus Pharmaceuticals (TARS) agreed to acquire privately held Alkeus Pharmaceuticals, gaining gildeuretinol (ALK-001), an investigational once-daily oral therapy for Stargardt disease, a rare ...

Aug 6 (Reuters) - Eye drugmaker Tarsus Pharmaceuticals (TARS.O), opens new tab said on Thursday it would acquire privately held Alkeus Pharmaceuticals in a ‌cash-and-stock deal worth up to $800 ...

Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3 retinal disease therapy, touted as a potential blockbuster. In return for $270 million in cash and ...

IRVINE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (“Tarsus”) today announced that it has entered into a securities purchase agreement with certain qualified ...

Adds a potential blockbuster opportunity with gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt disease, one of the ...

Irvine-based Tarsus Pharmaceuticals Inc. yesterday said Chief Commercial Officer Aziz Mottiwala will depart to become chief executive of an undisclosed publicly traded medical device company. Neera ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Tarsus Pharmaceuticals Inc. yesterday announced its acquisition of Palo Alto-based iRenix Medical Inc. and its late-stage ocular antiseptic candidate, IRX-101, for $75 million. IRX-101 has the ...

Tarsus Distribution has announced that CEO Emile Burger will step down from his role after leading the company through a period of sustained growth and expansion. Burger, who previously served as the ...